Table 5 |
||||||||
|
Primary outcomes for patients with PSC |
||||||||
|
Placebo (n = 6) |
Fluvoxamine (n = 5) |
|||||||
|
|
||||||||
|
Day 0 |
Day 14 |
Day 42 |
Day 70 |
Day 0 |
Day 14 |
Day 42 |
Day 70 |
|
|
|
||||||||
|
VAS Fatigue |
7.3 |
7.4 |
7.5 |
8.3 |
6.4 |
6.8 |
7.5 |
7.9 |
|
FFSS |
||||||||
|
Physical Domain |
14 |
13 |
9 |
9 |
28 |
27 |
26 |
28 |
|
Cognitive Domain |
8 |
11 |
8 |
7 |
20 |
20 |
19 |
18 |
|
Social Domain |
17 |
12 |
11 |
13 |
48 |
49 |
47 |
48 |
|
MFI |
||||||||
|
General Fatigue |
18 |
18 |
17 |
17 |
19 |
19 |
19 |
20 |
|
Physical Fatigue |
13 |
15 |
14 |
13 |
18 |
19 |
19 |
19 |
|
Reduction Activity |
12 |
12 |
11 |
12 |
18 |
18 |
17 |
20 |
|
Reduction Motivation |
10 |
10 |
8 |
8 |
18 |
17 |
18 |
16 |
|
Mental Fatigue |
12 |
10 |
10 |
11 |
14 |
14 |
13 |
13 |
|
|
||||||||
|
Results are expressed as median scores. |
||||||||
|
ter Borg et al. BMC Gastroenterology 2004 4:13 doi:10.1186/1471-230X-4-13 |
||||||||
